JPWO2016072105A1 - 重層上皮組織形成能を有する細胞、及びその製造方法 - Google Patents
重層上皮組織形成能を有する細胞、及びその製造方法 Download PDFInfo
- Publication number
- JPWO2016072105A1 JPWO2016072105A1 JP2016557462A JP2016557462A JPWO2016072105A1 JP WO2016072105 A1 JPWO2016072105 A1 JP WO2016072105A1 JP 2016557462 A JP2016557462 A JP 2016557462A JP 2016557462 A JP2016557462 A JP 2016557462A JP WO2016072105 A1 JPWO2016072105 A1 JP WO2016072105A1
- Authority
- JP
- Japan
- Prior art keywords
- gene
- epithelial tissue
- cell
- cells
- ability
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000000981 epithelium Anatomy 0.000 title claims abstract description 195
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 38
- 210000004027 cell Anatomy 0.000 claims abstract description 239
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 147
- 210000001082 somatic cell Anatomy 0.000 claims abstract description 84
- 210000002950 fibroblast Anatomy 0.000 claims description 74
- 101150085321 Tfap2a gene Proteins 0.000 claims description 36
- 238000000034 method Methods 0.000 claims description 36
- 101150101605 BNC1 gene Proteins 0.000 claims description 35
- 101100272646 Homo sapiens BNC1 gene Proteins 0.000 claims description 35
- 101100449524 Homo sapiens GRHL2 gene Proteins 0.000 claims description 31
- 239000000126 substance Substances 0.000 claims description 30
- 238000002360 preparation method Methods 0.000 claims description 29
- 238000012360 testing method Methods 0.000 claims description 29
- 230000002500 effect on skin Effects 0.000 claims description 22
- 210000002919 epithelial cell Anatomy 0.000 claims description 21
- 101150106035 EHF gene Proteins 0.000 claims description 19
- 101150060333 GATA3 gene Proteins 0.000 claims description 19
- 101000642523 Homo sapiens Transcription factor SOX-7 Proteins 0.000 claims description 19
- 101150012407 OVOL1 gene Proteins 0.000 claims description 19
- 101150106167 SOX9 gene Proteins 0.000 claims description 19
- 101710140697 Tumor protein 63 Proteins 0.000 claims description 19
- 101150118813 ZBED2 gene Proteins 0.000 claims description 19
- 101150052039 ZNF165 gene Proteins 0.000 claims description 19
- 101000737551 Homo sapiens Ceramide synthase 3 Proteins 0.000 claims description 18
- 210000001519 tissue Anatomy 0.000 claims description 15
- 101001069926 Homo sapiens Grainyhead-like protein 3 homolog Proteins 0.000 claims description 14
- 101100452004 Homo sapiens PPP1R13L gene Proteins 0.000 claims description 14
- 101100452005 Mus musculus Ppp1r13l gene Proteins 0.000 claims description 14
- 101150097703 PPP1R13L gene Proteins 0.000 claims description 14
- 101150025003 grhl1 gene Proteins 0.000 claims description 14
- 101150035115 ARNTL2 gene Proteins 0.000 claims description 13
- 101150076273 ESRP1 gene Proteins 0.000 claims description 13
- 101000861406 Homo sapiens Forkhead box protein Q1 Proteins 0.000 claims description 13
- 101100510266 Homo sapiens KLF4 gene Proteins 0.000 claims description 13
- 101100242392 Homo sapiens OVOL2 gene Proteins 0.000 claims description 13
- 101150016847 IRX4 gene Proteins 0.000 claims description 13
- 101150070299 KLF4 gene Proteins 0.000 claims description 13
- 101150060694 Mapk13 gene Proteins 0.000 claims description 13
- 101150116983 znf750 gene Proteins 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 101001053438 Homo sapiens Iroquois-class homeodomain protein IRX-2 Proteins 0.000 claims description 11
- 101150047694 ID1 gene Proteins 0.000 claims description 11
- 108091057508 Myc family Proteins 0.000 claims description 11
- 238000012546 transfer Methods 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 210000004400 mucous membrane Anatomy 0.000 claims description 9
- 101100109000 Homo sapiens TFAP2C gene Proteins 0.000 claims description 8
- 101150001277 TFAP2C gene Proteins 0.000 claims description 8
- 210000002536 stromal cell Anatomy 0.000 claims description 8
- 230000017423 tissue regeneration Effects 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 6
- 210000000577 adipose tissue Anatomy 0.000 claims description 6
- 229920001436 collagen Polymers 0.000 claims description 6
- 210000005087 mononuclear cell Anatomy 0.000 claims description 6
- 230000005855 radiation Effects 0.000 claims description 6
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 102100027881 Tumor protein 63 Human genes 0.000 claims description 4
- 230000008929 regeneration Effects 0.000 claims description 4
- 238000011069 regeneration method Methods 0.000 claims description 4
- 210000005127 stratified epithelium Anatomy 0.000 claims description 4
- 108700026220 vif Genes Proteins 0.000 claims description 4
- 210000005259 peripheral blood Anatomy 0.000 claims description 2
- 239000011886 peripheral blood Substances 0.000 claims description 2
- 239000003560 cancer drug Substances 0.000 claims 1
- 210000002510 keratinocyte Anatomy 0.000 description 49
- 210000003491 skin Anatomy 0.000 description 40
- 239000002609 medium Substances 0.000 description 37
- 108700019146 Transgenes Proteins 0.000 description 20
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000000512 collagen gel Substances 0.000 description 14
- 239000013598 vector Substances 0.000 description 14
- 208000025865 Ulcer Diseases 0.000 description 12
- 230000011712 cell development Effects 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 12
- 210000000130 stem cell Anatomy 0.000 description 12
- 241000700605 Viruses Species 0.000 description 11
- 239000011575 calcium Substances 0.000 description 11
- 238000002493 microarray Methods 0.000 description 11
- 238000000926 separation method Methods 0.000 description 11
- 231100000397 ulcer Toxicity 0.000 description 11
- 238000012258 culturing Methods 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- 210000001626 skin fibroblast Anatomy 0.000 description 10
- 108700011259 MicroRNAs Proteins 0.000 description 9
- 210000004369 blood Anatomy 0.000 description 9
- 239000008280 blood Substances 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 238000005516 engineering process Methods 0.000 description 9
- 239000002679 microRNA Substances 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 239000001963 growth medium Substances 0.000 description 8
- 206010040943 Skin Ulcer Diseases 0.000 description 7
- 201000007717 corneal ulcer Diseases 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 210000001035 gastrointestinal tract Anatomy 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- 231100000019 skin ulcer Toxicity 0.000 description 7
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 6
- 208000004210 Pressure Ulcer Diseases 0.000 description 6
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 239000011521 glass Substances 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000004264 monolayer culture Methods 0.000 description 6
- 239000003590 rho kinase inhibitor Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 5
- 238000007796 conventional method Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000001172 regenerating effect Effects 0.000 description 5
- 210000004003 subcutaneous fat Anatomy 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 101000614436 Homo sapiens Keratin, type I cytoskeletal 14 Proteins 0.000 description 4
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 description 4
- 210000004087 cornea Anatomy 0.000 description 4
- 208000021921 corneal disease Diseases 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 239000012526 feed medium Substances 0.000 description 4
- 239000010410 layer Substances 0.000 description 4
- 206010065929 Cardiovascular insufficiency Diseases 0.000 description 3
- 206010056340 Diabetic ulcer Diseases 0.000 description 3
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 3
- 241000713666 Lentivirus Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 229960004857 mitomycin Drugs 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000013517 stratification Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- 230000008733 trauma Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 101150043700 ESRP2 gene Proteins 0.000 description 2
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 2
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 2
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- -1 L-Myc etc.) Proteins 0.000 description 2
- 108700026495 N-Myc Proto-Oncogene Proteins 0.000 description 2
- 102100030124 N-myc proto-oncogene protein Human genes 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 206010064996 Ulcerative keratitis Diseases 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 210000003683 corneal stroma Anatomy 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 210000003560 epithelium corneal Anatomy 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000000642 iatrogenic effect Effects 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007721 medicinal effect Effects 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 206010033675 panniculitis Diseases 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000002341 stratified epithelial cell Anatomy 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 description 1
- 102000038594 Cdh1/Fizzy-related Human genes 0.000 description 1
- 108091007854 Cdh1/Fizzy-related Proteins 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 206010009192 Circulatory collapse Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 206010018001 Gastrointestinal perforation Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100034227 Grainyhead-like protein 2 homolog Human genes 0.000 description 1
- 101001069929 Homo sapiens Grainyhead-like protein 2 homolog Proteins 0.000 description 1
- 108091066895 Homo sapiens miR-135b stem-loop Proteins 0.000 description 1
- 108091068991 Homo sapiens miR-141 stem-loop Proteins 0.000 description 1
- 108091070489 Homo sapiens miR-17 stem-loop Proteins 0.000 description 1
- 108091067627 Homo sapiens miR-182 stem-loop Proteins 0.000 description 1
- 108091067605 Homo sapiens miR-183 stem-loop Proteins 0.000 description 1
- 108091070490 Homo sapiens miR-18a stem-loop Proteins 0.000 description 1
- 108091070517 Homo sapiens miR-19a stem-loop Proteins 0.000 description 1
- 108091070519 Homo sapiens miR-19b-1 stem-loop Proteins 0.000 description 1
- 108091065166 Homo sapiens miR-200a stem-loop Proteins 0.000 description 1
- 108091069457 Homo sapiens miR-200b stem-loop Proteins 0.000 description 1
- 108091066023 Homo sapiens miR-200c stem-loop Proteins 0.000 description 1
- 108091067482 Homo sapiens miR-205 stem-loop Proteins 0.000 description 1
- 108091070496 Homo sapiens miR-20a stem-loop Proteins 0.000 description 1
- 108091067254 Homo sapiens miR-367 stem-loop Proteins 0.000 description 1
- 108091032930 Homo sapiens miR-429 stem-loop Proteins 0.000 description 1
- 108091070380 Homo sapiens miR-92a-1 stem-loop Proteins 0.000 description 1
- 108091070376 Homo sapiens miR-96 stem-loop Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108700021430 Kruppel-Like Factor 4 Proteins 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 101150039798 MYC gene Proteins 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 108091028141 MiR-203 Proteins 0.000 description 1
- 108091062154 Mir-205 Proteins 0.000 description 1
- 108091027559 Mir-96 microRNA Proteins 0.000 description 1
- 229930192392 Mitomycin Natural products 0.000 description 1
- 208000034493 Mucous membrane disease Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 239000012124 Opti-MEM Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010034567 Peripheral circulatory failure Diseases 0.000 description 1
- 101100247004 Rattus norvegicus Qsox1 gene Proteins 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 101150086694 SLC22A3 gene Proteins 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 238000011882 arthroplasty Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000003969 blast cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 230000024690 epidermis development Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000005128 keratinized epithelium Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000002826 magnetic-activated cell sorting Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 108091026375 miR-135b stem-loop Proteins 0.000 description 1
- 108091086065 miR-135b-2 stem-loop Proteins 0.000 description 1
- 108091058688 miR-141 stem-loop Proteins 0.000 description 1
- 108091091751 miR-17 stem-loop Proteins 0.000 description 1
- 108091069239 miR-17-2 stem-loop Proteins 0.000 description 1
- 108091041042 miR-18 stem-loop Proteins 0.000 description 1
- 108091023796 miR-182 stem-loop Proteins 0.000 description 1
- 108091029500 miR-183 stem-loop Proteins 0.000 description 1
- 108091062221 miR-18a stem-loop Proteins 0.000 description 1
- 108091050874 miR-19a stem-loop Proteins 0.000 description 1
- 108091086850 miR-19a-1 stem-loop Proteins 0.000 description 1
- 108091088468 miR-19a-2 stem-loop Proteins 0.000 description 1
- 108091028067 miR-19b-1 stem-loop Proteins 0.000 description 1
- 108091059199 miR-200a stem-loop Proteins 0.000 description 1
- 108091089775 miR-200b stem-loop Proteins 0.000 description 1
- 108091074450 miR-200c stem-loop Proteins 0.000 description 1
- 108091049679 miR-20a stem-loop Proteins 0.000 description 1
- 108091062637 miR-367 stem-loop Proteins 0.000 description 1
- 108091059135 miR-429 stem-loop Proteins 0.000 description 1
- 108091028159 miR-92a-1 stem-loop Proteins 0.000 description 1
- 108091086713 miR-96 stem-loop Proteins 0.000 description 1
- 108091070961 miR-96-3 stem-loop Proteins 0.000 description 1
- 108091070501 miRNA Proteins 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 239000011325 microbead Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 230000005501 phase interface Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011158 quantitative evaluation Methods 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 206010040560 shock Diseases 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000003207 subcutaneous adipocyte Anatomy 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005068 transpiration Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M1/00—Apparatus for enzymology or microbiology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5082—Supracellular entities, e.g. tissue, organisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- Plant Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Rheumatology (AREA)
Abstract
Description
項1. 重層上皮組織形成能を有する細胞に相対的に強発現する少なくとも1種の遺伝子を体細胞に導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
項2. GATA3遺伝子、OVOL1遺伝子、OVOL2遺伝子、ESRP1遺伝子、TFAP2A遺伝子、ID1遺伝子、GRHL1遺伝子、GRHL2遺伝子、GRHL3遺伝子、TP63遺伝子、DNP63A遺伝子、MAPK13遺伝子、ARNTL2遺伝子、BNC1遺伝子、LASS3遺伝子、EHF遺伝子、ZNF165遺伝子、ZNF750遺伝子、ZBED2遺伝子、IRX2遺伝子、IRX4遺伝子、SOX7遺伝子、SOX9遺伝子、FOXQ1遺伝子、PPP1R13L遺伝子、KLF4遺伝子及びc-MYC遺伝子から選択された一つ以上の遺伝子を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
項3. (1)TFAP2A遺伝子またはTFAP2C遺伝子、(2)GRHLファミリー遺伝子、(3)BNC1遺伝子及び(4)MYCファミリー遺伝子を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
項4. (1)TFAP2A遺伝子またはTFAP2C遺伝子、(2)GRHLファミリー遺伝子、(3)BNC1遺伝子、(4)MYCファミリー遺伝子及び(5)重層上皮組織形成能を有する細胞に相対的に強発現する少なくとも1種の遺伝子を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
項5. (1)TFAP2A遺伝子、(2)GRHL2遺伝子、(3)BNC1遺伝子、(4)c-MYC遺伝子を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
項6. GATA3遺伝子、TFAP2A遺伝子、GRHL2遺伝子、TP63遺伝子、BNC1遺伝子、EHF遺伝子、ZNF165遺伝子及びc-MYC遺伝子を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
項7. OVOL1遺伝子、TFAP2A遺伝子、GRHL2遺伝子、BNC1遺伝子、LASS3遺伝子、ZBED2遺伝子、SOX7遺伝子、SOX9遺伝子及びc-MYC遺伝子を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
項8. GATA3遺伝子、OVOL1遺伝子、OVOL2遺伝子、ESRP1遺伝子、TFAP2A遺伝子、ID1遺伝子、GRHL1遺伝子、GRHL2遺伝子、GRHL3遺伝子、TP63遺伝子、DNP63A遺伝子、MAPK13遺伝子、ARNTL2遺伝子、BNC1遺伝子、LASS3遺伝子、EHF遺伝子、ZNF165遺伝子、ZNF750遺伝子、ZBED2遺伝子、IRX2遺伝子、IRX4遺伝子、SOX7遺伝子、SOX9遺伝子、FOXQ1遺伝子、PPP1R13L遺伝子、KLF4遺伝子及びc-MYC遺伝子を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
項9. 前記体細胞がヒト由来である、項1乃至項8の何れか1項に記載の製造方法。
項10. 前記体細胞が皮膚線維芽細胞である、項1乃至9の何れか1項に記載の重層上皮組織形成能を有する細胞の製造方法。
項11. 前記体細胞が脂肪組織由来間質細胞である、項1乃至9の何れか1項に記載の重層上皮組織形成能を有する細胞の製造方法。
項12. 前記体細胞が末梢循環血液中の単核球である、項1乃至9の何れか1項に記載の重層上皮組織形成能を有する細胞の製造方法。
項13. 項1乃至12の何れか1項に記載の製造方法により製造される重層上皮組織形成能を有する細胞。
項14. 項13に記載の重層上皮組織形成能を有する細胞を含む、細胞製剤。
項15. 足場材料を含む項14に記載の細胞製剤。
項16. 前記足場材料がコラーゲンである、項15に記載の細胞製剤。
項17. 前記細胞製剤は、重層上皮再生用、皮膚組織再生用、粘膜組織再生用又は角膜組織再生用である項14乃至16の何れか1項に記載の細胞製剤。
項18. 前記細胞製剤がシート状の上皮細胞シートである項14乃至17の何れか1項に記載の細胞製剤。
項19. 項12に記載の重層上皮組織形成能を有する細胞を非ヒト哺乳動物に投与して、前記哺乳動物の体内で前記重層上皮組織形成能を有する細胞から重層上皮組織を形成させることにより製造される、重層上皮組織を形成させた非ヒト哺乳動物。
項20. 項19に記載の非ヒト哺乳動物に被験物質を投与し、上皮組織に対する被験物質の薬効を判定する工程を含む、上皮組織に対する被験物質の薬効を判定する方法。
項21. 項19に記載の非ヒト哺乳動物に抗がん剤や放射線などのストレスを負荷し、上皮組織に対するストレスを判定する工程を含む、上皮組織に対する外的要因の影響を判定する方法。
項22. 項1乃至8の何れか1項に記載の体細胞に遺伝子導入される遺伝子を含む、重層上皮組織形成能を有する細胞調整用組成物。
項23. 前記遺伝子が、体細胞に導入可能な形態で含まれる、項21に記載の細胞調整用組成物。
項24. 項13に記載の重層上皮組織形成能を有する細胞を培養して作製された上皮様組織。
項25. 動物から取り出された体細胞に、項1乃至項8の何れか1項に記載の遺伝子を遺伝子導入して製造された重層上皮組織形成能を有する細胞を培養して作製された上皮様組織に対し、被験物質を投与し、前記上皮様組織に対する被験物質の薬効を分析する工程を含む、上皮組織に対する被験物質の薬効の分析方法。
項26. 動物から取り出された体細胞に、項1乃至項8の何れか1項に記載の遺伝子を遺伝子導入して製造された重層上皮組織形成能を有する細胞を培養して作製された上皮様組織に対し、抗がん剤や放射線などのストレスを負荷し、前記上皮様組織に対するストレスを分析する工程を含む、上皮組織に対する外的要因の影響の分析方法。
項27. 項1乃至8の何れか1項に記載の遺伝子を体細胞に遺伝子導入するために特化したベクターのキット。
本発明において、「重層上皮組織形成能を有する細胞」とは、表皮、粘膜や角膜など、外界に触れる部位において身体内部を機械的障害、感染などの外的要因から保護する重層上皮の前駆細胞もしくは幹細胞として働く能力を備えている細胞(換言すれば、上皮幹細胞)のことを意味し、生体内の体細胞であるケラチノサイト、消化管上皮細胞、角膜上皮細胞も、本発明によって人工的に体細胞から誘導された細胞も含む。重層上皮組織形成能を有する細胞は、単層培養条件下において培養条件を調整することによって、自己複製能と終分化の双方の特性を呈する。又は、重層上皮組織形成能を有する細胞は、皮膚線維芽細胞などを含んだコラーゲンゲルを担体とした3次元培養においては重層上皮組織様の構造体を形成する能力をもつ。
以下に、実施例等に基づいて本発明を詳細に説明するが、本発明はこれらによって限定されるものではない。
上記解析結果を踏まえ、表2に記載の27種の導入遺伝子を選択し、体細胞に導入するためのレンチウイルスベクターを準備した。候補として選択した転写因子、マイクロRNAおよび強制発現、発現抑制のために用意したレンチウイルスベクターの仔細を表2に示す。PPP1R13L遺伝子については、2つのtranscript variantについて、それぞれベクターを準備した。
表2に記載の27種の遺伝子から、IRX2遺伝子及びIRX4遺伝子の2種を除いた残りの25種の遺伝子を導入遺伝子として皮膚線維芽細胞に導入した。基本的な実験条件、実験方法は、実施例1と同様である。実施例1と同様に、25種の導入遺伝子を皮膚線維芽細胞に導入し、培養した誘導線維芽細胞を得た。図13は、上述の方法に従い作製した誘導線維芽細胞のコロニーを示す図であり、左が高密度の領域、右が低密度の領域を示す。図13から、実施例2の誘導線維芽細胞のコロニーは、周囲のフィーダーおよび誘導されていない細胞と明瞭な境界をもっており、コロニーの辺縁には平坦な細胞が位置し、中央にむかって重積しており、図7のケラチノサイトのコロニー類似の形態を示している。
・参考文献1:Shalom-Feuerstein R, Lena AM, Zhou H, De La Forest Divonne S, Van Bokhoven H, Candi E, Melino G, Aberdam D. Cell Death Differ. 2011;18(5):887-96.
・参考文献2:Kurita M, Okazaki M, Kaminishi-Tanikawa A, Niikura M, Takushima A, Harii K. Connect Tissue Res. 2012;53(5):349-54.
・参考文献3:Kurita M, Okazaki M, Fujino T, Takushima A, Harii K. Biochem Biophys Res Commun. 2011 May 27;409(1):103-7.
・参考文献4:Chapman S1, Liu X, Meyers C, Schlegel R, McBride AA. J Clin Invest. 2010 Jul;120(7):2619-26
・参考文献5:Okazaki M, Yoshimura K, Fujiwara H, Suzuki Y, Harii K. Plast Reconstr Surg. 2003 Sep;112(3):784-92.
・参考文献6:Okazaki M, Yoshimura K, Suzuki Y, Harii K. Plast Reconstr Surg. 2003 Sep;112(3):784-92.
Claims (27)
- 重層上皮組織形成能を有する細胞に相対的に強発現する少なくとも1種の遺伝子を体細胞に導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
- GATA3遺伝子、OVOL1遺伝子、OVOL2遺伝子、ESRP1遺伝子、TFAP2A遺伝子、ID1遺伝子、GRHL1遺伝子、GRHL2遺伝子、GRHL3遺伝子、TP63遺伝子、DNP63A遺伝子、MAPK13遺伝子、ARNTL2遺伝子、BNC1遺伝子、LASS3遺伝子、EHF遺伝子、ZNF165遺伝子、ZNF750遺伝子、ZBED2遺伝子、IRX2遺伝子、IRX4遺伝子、SOX7遺伝子、SOX9遺伝子、FOXQ1遺伝子、PPP1R13L遺伝子、KLF4遺伝子及びc-MYC遺伝子から選択された一つ以上の遺伝子を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
- (1)TFAP2A遺伝子またはTFAP2C遺伝子、
(2)GRHLファミリー遺伝子から選択された少なくとも一種の遺伝子、
(3)BNC1遺伝子及び
(4)MYCファミリー遺伝子から選択された少なくとも一種の遺伝子
を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。 - (1)TFAP2A遺伝子またはTFAP2C遺伝子、
(2)GRHLファミリー遺伝子から選択された少なくとも一種の遺伝子、
(3)BNC1遺伝子、
(4)MYCファミリー遺伝子から選択された少なくとも一種の遺伝子及び
(5)重層上皮組織形成能を有する細胞に相対的に強発現する少なくとも1種の遺伝子
を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。 - (1)TFAP2A遺伝子、(2)GRHL2遺伝子、(3)BNC1遺伝子、(4)c-MYC遺伝子を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
- GATA3遺伝子、TFAP2A遺伝子、GRHL2遺伝子、TP63遺伝子、BNC1遺伝子、EHF遺伝子、ZNF165遺伝子及びc-MYC遺伝子を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
- OVOL1遺伝子、TFAP2A遺伝子、GRHL2遺伝子、BNC1遺伝子、LASS3遺伝子、ZBED2遺伝子、SOX7遺伝子、SOX9遺伝子及びc-MYC遺伝子を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
- GATA3遺伝子、OVOL1遺伝子、OVOL2遺伝子、ESRP1遺伝子、TFAP2A遺伝子、ID1遺伝子、GRHL1遺伝子、GRHL2遺伝子、GRHL3遺伝子、TP63遺伝子、DNP63A遺伝子、MAPK13遺伝子、ARNTL2遺伝子、BNC1遺伝子、LASS3遺伝子、EHF遺伝子、ZNF165遺伝子、ZNF750遺伝子、ZBED2遺伝子、IRX2遺伝子、IRX4遺伝子、SOX7遺伝子、SOX9遺伝子、FOXQ1遺伝子、PPP1R13L遺伝子、KLF4遺伝子及びc-MYC遺伝子を体細胞に遺伝子導入する工程を含む、重層上皮組織形成能を有する細胞の製造方法。
- 前記体細胞がヒト由来である、請求項1乃至8の何れか1項に記載の製造方法。
- 前記体細胞が皮膚線維芽細胞である、請求項1乃至9の何れか1項に記載の重層上皮組織形成能を有する細胞の製造方法。
- 前記体細胞が脂肪組織由来間質細胞である、請求項1乃至9の何れか1項に記載の重層上皮組織形成能を有する細胞の製造方法。
- 前記体細胞が末梢循環血液中の単核球である、請求項1乃至9の何れか1項に記載の重層上皮組織形成能を有する細胞の製造方法。
- 請求項1乃至12の何れか1項に記載の製造方法により製造される重層上皮組織形成能を有する細胞。
- 請求項13に記載の重層上皮組織形成能を有する細胞を含む、細胞製剤。
- 足場材料を含む請求項14に記載の細胞製剤。
- 前記足場材料がコラーゲンである、請求項15に記載の細胞製剤。
- 前記細胞製剤は、重層上皮再生用、皮膚組織再生用、粘膜組織再生用又は角膜組織再生用である請求項14乃至16の何れか1項に記載の細胞製剤。
- 前記細胞製剤がシート状の上皮細胞シートである請求項14乃至17の何れか1項に記載の細胞製剤。
- 請求項13に記載の重層上皮組織形成能を有する細胞を非ヒト哺乳動物に投与して、前記哺乳動物の体内で前記重層上皮組織形成能を有する細胞から重層上皮組織を形成させることにより製造される、重層上皮組織を形成させた非ヒト哺乳動物。
- 請求項19に記載の非ヒト哺乳動物に被験物質を投与し、上皮組織に対する被験物質の薬効を判定する工程を含む、上皮組織に対する被験物質の薬効を判定する方法。
- 請求項19に記載の非ヒト哺乳動物に抗がん剤や放射線などのストレスを負荷し、上皮組織に対するストレスを判定する工程を含む、上皮組織に対する外的要因の影響を判定する方法。
- 請求項1乃至8の何れか1項に記載の体細胞に遺伝子導入される遺伝子を含む、重層上皮組織形成能を有する細胞調整用組成物。
- 前記遺伝子が、体細胞に導入可能な形態で含まれる、請求項22に記載の細胞調整用組成物。
- 請求項13に記載の重層上皮組織形成能を有する細胞から分化した上皮細胞組織。
- 動物から取り出された体細胞に、請求項1乃至項8の何れか1項に記載の遺伝子を遺伝子導入して製造された重層上皮組織形成能を有する細胞から分化した上皮細胞組織に対し、被験物質を投与し、上皮組織に対する被験物質の薬効を判定する工程を含む、上皮組織に対する被験物質の薬効の分析方法。
- 動物から取り出された体細胞に、請求項1乃至項8の何れか1項に記載の遺伝子を遺伝子導入して製造された重層上皮組織形成能を有する細胞から分化した上皮細胞組織に対し、抗がん剤や放射線などのストレスを負荷し、上皮組織に対するストレスを判定する工程を含む、上皮組織に対する外的要因の影響の分析方法。
- 請求項1乃至8の何れか1項に記載の遺伝子を体細胞に遺伝子導入するためのキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2014223990 | 2014-11-04 | ||
JP2014223990 | 2014-11-04 | ||
PCT/JP2015/059872 WO2016072105A1 (ja) | 2014-11-04 | 2015-03-30 | 重層上皮組織形成能を有する細胞、及びその製造方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020009177A Division JP2020072731A (ja) | 2014-11-04 | 2020-01-23 | 重層上皮組織形成能を有する細胞、及びその製造方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPWO2016072105A1 true JPWO2016072105A1 (ja) | 2017-09-14 |
JP6654323B2 JP6654323B2 (ja) | 2020-02-26 |
Family
ID=55908842
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016557462A Active JP6654323B2 (ja) | 2014-11-04 | 2015-03-30 | 重層上皮組織形成能を有する細胞、及びその製造方法 |
JP2020009177A Pending JP2020072731A (ja) | 2014-11-04 | 2020-01-23 | 重層上皮組織形成能を有する細胞、及びその製造方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020009177A Pending JP2020072731A (ja) | 2014-11-04 | 2020-01-23 | 重層上皮組織形成能を有する細胞、及びその製造方法 |
Country Status (3)
Country | Link |
---|---|
US (1) | US11041146B2 (ja) |
JP (2) | JP6654323B2 (ja) |
WO (1) | WO2016072105A1 (ja) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008508968A (ja) * | 2004-08-13 | 2008-03-27 | フェニオン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト | 皮膚等価物を製造するための架橋コラーゲンマトリックス |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2005083075A1 (ja) * | 2004-03-02 | 2007-11-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 表皮分化に関与する新規遺伝子、およびその利用 |
AU2011316830A1 (en) * | 2010-10-22 | 2013-05-02 | Biotime Inc. | Methods of modifying transcriptional regulatory networks in stem cells |
-
2015
- 2015-03-30 US US15/523,571 patent/US11041146B2/en active Active
- 2015-03-30 WO PCT/JP2015/059872 patent/WO2016072105A1/ja active Application Filing
- 2015-03-30 JP JP2016557462A patent/JP6654323B2/ja active Active
-
2020
- 2020-01-23 JP JP2020009177A patent/JP2020072731A/ja active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008508968A (ja) * | 2004-08-13 | 2008-03-27 | フェニオン・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト | 皮膚等価物を製造するための架橋コラーゲンマトリックス |
Non-Patent Citations (6)
Title |
---|
H.TSENG, ET AL: "Basonuclin in murine corneal and lens epithelia correlates with cellular maturation and proliferativ", DIFFERENTIATION, vol. Vol.65, JPN6015025687, 1999, pages 221 - 227, XP026790095, DOI: doi:10.1046/j.1432-0436.1999.6540221.x * |
K.A.HONEYCUTT, ET AL: "Genes Involved in Stem Cell Fate Decisions and Commitment to Differentiation Play a Role in Skin Dis", JOURNAL OF INVESTIGATIVE DERMATOLOGY SYMPOSIUM PROCEEDINGS, vol. Vol.9(3), JPN6015025688, 2004, pages 261 - 268, XP009110353, DOI: doi:10.1111/j.1087-0024.2004.09312.x * |
S.S.MCDADE, ET AL: "Genome-wide analysis of p63 binding sites identifies AP-2 factors as co-regulators of epidermal diff", NUCLEIC ACIDS RESEARCH, vol. 40, no. 15, JPN6015025685, 2012, pages 7190 - 7206, XP055278748, DOI: doi:10.1093/nar/gks389 * |
Y.BOGLEV, ET AL: "The unique and cooperative roles of the Grainy head-like transcription factors in epidermal develope", DEVELOPMENTAL BIOLOGY, vol. Vol.349, JPN6015025686, 2011, pages 512 - 522, XP027587798 * |
栗田 昌和 他: "皮膚潰瘍上皮化促進を目的とした線維芽細胞からケラチノサイトへの直接転換のこころみ", 第22回日本形成外科学会基礎学術集会 プログラム・抄録集, JPN6015025683, 10 October 2013 (2013-10-10), pages p.115 (O-124) * |
栗田 昌和 他: "遺伝子導入による線維芽細胞からケラチノサイトへの直接転換方法の開発", 第23回日本形成外科学会基礎学術集会 プログラム・抄録集, JPN6015025684, 12 September 2014 (2014-09-12), pages p.63 (O2-30) * |
Also Published As
Publication number | Publication date |
---|---|
US20180155695A1 (en) | 2018-06-07 |
US11041146B2 (en) | 2021-06-22 |
WO2016072105A1 (ja) | 2016-05-12 |
JP2020072731A (ja) | 2020-05-14 |
JP6654323B2 (ja) | 2020-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7027484B2 (ja) | 瘻の治療における脂肪組織由来間質幹細胞の使用 | |
Tian et al. | Myogenic differentiation of human bone marrow mesenchymal stem cells on a 3D nano fibrous scaffold for bladder tissue engineering | |
Rohaina et al. | Reconstruction of limbal stem cell deficient corneal surface with induced human bone marrow mesenchymal stem cells on amniotic membrane | |
JP6821908B2 (ja) | 哺乳動物種における誘導組織再生のための組成物および方法 | |
JP7055638B2 (ja) | 幹細胞からの筋肉系列細胞の生成 | |
US20060247195A1 (en) | Method of altering cell properties by administering rna | |
Moon et al. | A system for treating ischemic disease using human embryonic stem cell-derived endothelial cells without direct incorporation | |
WO2014153294A1 (en) | Method to expand and transduce cultured human small and large intestinal stem cells | |
CN111944748A (zh) | 一种用于治疗心肌梗死的高表达il-10的人脂肪间充质干细胞外泌体及其用途 | |
CN111500578A (zh) | 调控ADSCs成骨分化及组织再生Circ RNA-FTO及其应用 | |
Day | Epithelial stem cells and tissue engineered intestine | |
JP7473967B2 (ja) | 扁桃由来間葉系幹細胞から運動神経細胞の分化方法 | |
JP2017538411A (ja) | 組織適用におけるlgr4、lgr5およびlgr6発現上皮幹細胞を用いた最小限分極機能性細胞微細凝集塊単位の開発および使用のための方法 | |
JP6654323B2 (ja) | 重層上皮組織形成能を有する細胞、及びその製造方法 | |
CN111925983A (zh) | 一种用于治疗心肌梗死的高表达il-10的人脂肪间充质干细胞外泌体的制备方法 | |
JP2022527507A (ja) | 細胞外小胞を用いる組織再生の誘導 | |
WO2020190672A1 (en) | Cardiomyocyte-derived exosomes inducing regeneration of damaged heart tissue | |
KR102306231B1 (ko) | 편도 유래 중간엽 줄기세포로부터 건 세포의 분화방법 | |
WO2019032995A1 (en) | HUMAN ADIPOSE TISSUE PROGENITORS FOR AUTOLOGOUS CELLULAR THERAPY OF LIPODYSTROPHY | |
US20230016479A1 (en) | Method for preparing mesenchymal stem cells having improved viability through anti-cancer virus introduction | |
US20230248776A1 (en) | Osteoblasts differentiated from mesenchymal stem cells and composition for treating bone disease comprising same | |
Wu et al. | The role of hSCs in promoting neural differentiation of hUC-MSCs in spinal cord injury | |
Yang et al. | Application of human umbilical cord mesenchymal stem cells in spinal cord injury | |
Gila et al. | Gene-edited cells: novel allogeneic gene/cell therapy for epidermolysis bullosa | |
WO2019093047A1 (ja) | インビトロでの機能的な外分泌腺の製造方法、および、当該方法によって製造される外分泌腺 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20180302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20180302 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180322 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180328 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190305 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20190605 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191105 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20191205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20191225 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20200123 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6654323 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |